Final Draft narrative December 6, 2012 - This strategic plan, developed through the joint collaboration of all stakeholders in the different sectors is aimed at harnessing and bringing together all the stakeholders who have a role in the prevention, detection and management of epidemic and infectiou...s diseases in the country. The plan describes the common epidemic and infectious diseases, the measures that need to be undertaken to ensure their control, the key partners and their roles and sets out milestones to monitor progress.
more
An international field study by African and German theologicans and health workers.
NATIONAL TUBERCULOSIS AND LEPROSY PROGRAMME
A scale to measure (social) participation for use in rehabilitation, stigma reduction and social integration programmes
Based on further analysis of the 2004 Kenya Service Provision Assessment Survey
Towards attaining the highest standard Health.
National Tuberclosis and
Leprosy Programme (NTLP)
Reference Manual for Programme Managers on Accreditation Process
Strengthening competency based training of health care providers for Reproductive Maternal Newborn Child & Adolescenct Health (RMNCH + A) services
Working with limited resources in armed conflict and other situations of violence. Vol.2
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov...ide population-wide access to essential medicines.
Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products.
This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
more